Combined predictive performance of age and neutrophilic percentage on admission for severe novel coronavirus disease 2019

Yuhong Chen¹ | Haijun Zhi² | Kun Zhang¹ | Guijun Zhu¹ | Lixia Liu¹ | Xixin Yan³ | Zhigang Cai³ | Congcong Zhao¹ | Zhenjie Hu¹

¹Department of Intensive Care Unit, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China
²Emergency Department, Cangzhou Central Hospital, Cangzhou, China
³Department of Respiration, Hebei Medical University Second Affiliated Hospital, Shijiazhuang, China

Correspondence
Zhenjie Hu, Department of Intensive Care Unit, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, 12 Jiankang Road, Shijiazhuang, Hebei 050011, China. Email: syicu@vip.sina.com

Funding information
This study was supported by the Department of Science and Technology of Hebei Province of China (20277707D).

Abstract
Background: Novel coronavirus disease 2019 (COVID-19) poses a huge threat to the global public health. This study aimed to identify predictive indicators of severe COVID-19.

Methods: We retrospectively collected clinical data on hospital admission of all patients with severe COVID-19 and a control cohort (1:1) of gender- and hospital-matched patients with mild disease from 13 designated hospitals in the Hebei Province between 22 January and 15 April 2020.

Results: A total of 104 patients (52 with severe COVID-19 and 52 with mild disease) were included. Only age, fever, duration from symptom onset to confirmation, respiratory rate, percutaneous oxygen saturation (SpO₂) and neutrophilic percentage were independent predictors of severe COVID-19. Age and neutrophilic percentage performed best in predicting severe COVID-19, followed by SpO₂. 'Age + neutrophilic percentage' (the sum of age and neutrophilic percentage) (area under the curve [AUC] 0.900, 95% confidence interval [CI] 0.825-0.950, P < .001) and 'age and neutrophilic percentage' (the prediction probability of age and neutrophilic percentage for severe type obtained by logistic regression analysis) (AUC 0.899, 95% CI 0.824-0.949, P < .001) had excellent predictive performance for severe type. The optimal cut-off for 'age + neutrophilic percentage' was >119.1 (sensitivity, 86.5%; specificity, 84.6%; Youden index, 0.712).

Conclusion: The combination of age and neutrophil percentage could effectively predict severe COVID-19. The sum of age and neutrophil percentage was recommended for clinical application because of its excellent predictive value and practicability.

Trail registration: China Clinical Trial Registry, number ChiCTR2000030226. Registered 26 February 2020-Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=49855

Abbreviations: AUC, area under the curve; BUN, blood urea nitrogen; CI, confidence interval; COVID-19, novel coronavirus disease 2019; CT, computed tomography; FiO₂, fraction of inspired oxygen; PaO₂, partial pressure of oxygen; ROC, receiver operator characteristic; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SpO₂, percutaneous oxygen saturation.
BACKGROUND

In December 2019, the first novel coronavirus disease 2019 (COVID-19) epidemic began in Wuhan, posing a huge threat to the global public health. Studies have shown that most patients with COVID-19 are asymptomatic or mild and about 20% of patients develop critical pneumonia leading to multiple organ dysfunction or even death. The treatment of severe cases has become a major challenge, and the early recognition of severe forms of COVID-19 is essential for timely triaging of patients. However, there are no reliable indicators to predict disease severity. The objective of this study was to identify predictive indicators of severe COVID-19.

METHODS

2.1 Study design and population

This multicenter, retrospective observational trial enrolled 327 patients with COVID-19 from 13 designated hospitals in the Hebei Province, China between 22 January and 15 April 2020. The inclusion criteria were diagnosis of COVID-19 by laboratory confirmation and local health authority. Patients aged ≤18 years, those with hospital length of stay ≤24 hours, and pregnant patients were not included. Finally, 52 patients with severe COVID-19 and a control cohort (1:1) of gender- and hospital-matched patients with mild type were included in the final analysis. Severe-type patients were categorised based on the Chinese Clinical Guidelines for COVID Pneumonia Diagnosis and Treatment (7th edition) and should meet at least one of the following criteria: (a) respiratory distress, a respiratory rate >30 breaths per minute, (b) percutaneous oxygen saturation (SpO₂) <93% under resting conditions or (c) partial pressure of oxygen (PaO₂)/fraction of inspired oxygen (FiO₂) ≤300 mmHg (1 mmHg = 0.133 kPa). Patients with mild type should meet the following criteria: (a) mild clinical symptoms or (b) mild or no lesions on imaging.

2.2 Data collection

Data were collected by accessing clinical medical records, nursing records and laboratory and radiological examination records. In the case of missing or uncertain data, we obtained them by direct communication with the managing physician. The data were reviewed by a trained team of physicians.

The recorded information included demographic characteristics, exposure history, chronic medical history, surgical history, symptoms from onset to hospital admission, vital signs on hospital admission, chest-computed tomography (CT) findings on admission, laboratory findings on admission, treatment during the illness course, extrapulmonary comorbidities during the illness course, duration of hospital stay, and mortality.

2.3 Statistical analysis

All analyses were performed using SPSS version 26.0 (IBM, USA). Categorical data were presented as numbers and percentages and compared using Pearson’s chi-square test or Fisher’s exact probability test. The normality of continuous variables was examined using the Kolmogorov-Smirnov test. Continuous variables without and with a normal distribution were compared using non-parametric tests and independent-sample t tests, respectively. Binary logistic regression was performed to identify the independent predictors of severe COVID-19. The prediction probability of the combined predictors for severe type was obtained by logistic regression analysis. The predictive performance of the independent predictors for severe type was analysed using receiver operator characteristic (ROC) curves. Delong’s test was used to compare area under the curves.
(AUCs) between each predictor using MedCalc version 18.2.1 (MedCalc Software Ltd, Ostend, Belgium). $P < .05$ was considered statistically significant.

3 | RESULTS

3.1 | Epidemiological characteristics and symptoms from onset to hospital admission

By 15 April 2020, 327 patients with COVID-19 were diagnosed, including 57 (17.43%) severe-type patients. Finally, 52 severe-type patients and 52 gender- and hospital-matched mild-type patients were included in this study. The main reasons for exclusion of severe-type patients were lack of clinical data ($n = 2$) and death within 24 hours ($n = 3$) (Figure 1).

Severe-type patients were older than mild-type patients ($P < .05$). In the severe type, there were fewer cases of exposure to confirmed patients ($P = .001$), more cases with Wuhan contact history ($P = .070$), and more patients had chronic medical history (hypertension, diabetes, cardiovascular disease and pulmonary disease), surgical history, fever and expectoration symptoms ($P < .05$) than in the mild type (Table 1). The duration from symptom onset to confirmation in severe-type patients was longer than in mild-type patients ($P < .001$) (Table 1). In addition, cases with exposure to confirmed patients had a longer duration from symptom onset to confirmation than those who had no exposure ($P < .05$).

3.2 | Vital signs, laboratory findings and imaging findings on hospital admission

The respiratory rate was higher, and $\text{SpO}_2$ was lower in severe-type patients than in mild-type patients ($P < .05$). More severe-type patients received mechanical ventilation than mild-type patients ($P < .05$) (Table 2).

3.3 | Treatment, comorbidities and outcomes

Nearly all patients received antiviral agents and traditional Chinese medicine in both groups. Antibiotic therapy, glucocorticoid treatment and vasoactive drug administration were more common in severe-type patients than in mild-type patients ($P < .001$). Moreover, severe-type patients received more antifungal therapy than mild-type patients, but the difference was not significant ($P = .126$) (Table 3).

All severe-type patients had acute respiratory distress syndrome, and 19 (36.5%), 11 (21.2%) and two (3.8%) of them received mechanical ventilation, prone position ventilation and extracorporeal membrane oxygenation therapy, respectively (Table 3).

More severe-type patients had extrapulmonary comorbidities than mild-type patients ($P < .001$). No mild-type patient had cardiac injury, acute kidney injury or gastrointestinal bleeding. Additionally, two (3.8%) mild-type and four (7.7%) severe-type patients had liver dysfunction (Table 3). The clinical outcome was worse in severe-type patients than in mild-type patients with three (5.8%) deaths among severe-type patients and none among mild-type patients. Furthermore, the length of hospital stay was

FIGURE 1 Study flow diagram
longer in severe-type patients than in mild-type patients ($P < .001$) (Table 3).

### 3.4 Logistic regression analysis of factors independently associated with severe COVID-19

In binary logistic regression, the significant predictors of severe type were age ($P < .001$), fever ($P = .013$), duration from symptom onset to confirmation ($P = .004$), respiratory rate ($P = .016$), $\text{SpO}_2$ ($P = .023$) and neutrophilic percentage ($P = .002$) (Table 4).

### 3.5 ROC curve analysis

Age (AUC 0.815, 95% confidence interval [CI] 0.727-0.884, $P < .001$) and neutrophilic percentage (AUC 0.814, 95% CI 0.726-0.884, $P < .001$) had the best predictive value with high specificity for severe type, followed by $\text{SpO}_2$ (AUC 0.811, 95% CI 0.723-0.881, $P < .001$). The performance of fever, duration from symptom onset to confirmation and respiratory rate in predicting severe type were poor (Table 5 and Figure 2).

Given the good performance of age and neutrophilic percentage, we combined these two indicators as ‘age and neutrophilic percentage’.
TABLE 2  Vital signs, laboratory and imaging findings on hospital admission of the 104 patients with COVID-19

| Vital signs                             | All patients (n = 104) | Severe group (n = 52) | Mild group (n = 52) | P value |
|-----------------------------------------|------------------------|-----------------------|---------------------|---------|
| Temperature, °C                         | 36.8 (36.5, 37.6)      | 36.9 (36.7, 38.0)     | 36.8 (36.5, 37.3)   | .100    |
| Heart rate, beats per minute            | 86 ± 14                | 89 ± 16               | 84 ± 10             | .064    |
| Respiratory rate, breaths per minute    | 20 (19, 22)            | 21 (19, 24)           | 20 (18, 21)         | .018    |
| SpO₂, %                                 | 97.5 (95.0, 98.0)      | 95.0 (92.3, 97.0)     | 98.0 (98.0, 99.0)   | <.001   |
| Systemic blood pressure, mmHg           | 131 (120, 140)         | 132 (121, 140)        | 130 (118, 140)      | .607    |
| Diastolic blood pressure, mmHg          | 82 (72, 88)            | 82 (72, 88)           | 82 (72, 88)         | .614    |
| Mean arterial pressure, mmHg            | 97 (87, 106)           | 96 (87, 104)          | 98 (88, 106)        | .805    |
| Receiving mechanical ventilation        | 6 (5.8%)               | 6 (11.5%)             | 0 (0.0%)            | .035    |

| Blood routine                           |                        |                       |                     |         |
|-----------------------------------------|------------------------|-----------------------|---------------------|---------|
| White blood cell count, x 10⁹/L          | 5.36 (4.30, 7.20)      | 5.68 (4.77, 8.07)     | 5.27 (3.78, 6.84)   | .063    |
| Neutrophil count, x 10⁹/L               | 3.63 (2.57, 5.59)      | 4.42 (3.08, 7.35)     | 3.31 (2.27, 4.13)   | .001    |
| Neutrophilic percentage, %              | 71.45 (60.40, 81.30)   | 79.15 (70.43, 89.23)  | 63.40 (53.5, 72.55) | <.001   |
| Lymphocyte count, x 10⁹/L               | 1.01 (0.66, 1.48)      | 0.74 (0.49, 1.14)     | 1.42 (0.93, 1.89)   | <.001   |
| Lymphocyte percentage, %                | 20.40 (12.33, 29.83)   | 13.35 (6.03, 21.93)   | 26.90 (19.75, 35.28)| <.001   |
| C-reactive protein, mg/L                | 13.25 (4.18, 44.17)    | 43.86 (12.18, 85.39)  | 4.97 (1.35, 13.75)  | <.001   |

| Blood biochemistry                      |                        |                       |                     |         |
|-----------------------------------------|------------------------|-----------------------|---------------------|---------|
| Albumin, g/L                            | 39.2 ± 5.6             | 36.4 ± 5.2            | 42.0 ± 4.4          | <.001   |
| Direct bilirubin, mmol/L                | 3.90 (2.53, 5.80)      | 4.40 (2.70, 6.18)     | 3.50 (2.31, 5.69)   | .303    |
| Indirect bilirubin, mmol/L              | 8.35 (6.19, 11.18)     | 7.90 (5.83, 10.50)    | 8.70 (6.62, 12.18)  | .269    |
| Creatinine, μmol/L                      | 69.0 (56.0, 89.5)      | 67.0 (56.6 87.8)      | 72.7 (55.6, 91.5)   | .728    |
| Blood urea nitrogen, mmol/L             | 4.20 (3.03, 5.29)      | 4.60 (3.84, 6.89)     | 3.56 (2.73, 4.49)   | <.001   |
| Creatinine kinase, U/L                  | 67.5 (39.2, 148.3)     | 80.5 (42.8, 169.5)    | 61.0 (36.5, 122.8)  | .326    |

| Imaging findings                        |                        |                       |                     |         |
|-----------------------------------------|------------------------|-----------------------|---------------------|---------|
| Bilateral involvement                   | 88 (84.6%)             | 48 (92.3%)            | 40 (76.9%)          | .030    |
| Consolidation                           | 11 (10.6%)             | 6 (11.5%)             | 5 (9.6%)            | .750    |
| Ground-glass opacity                    | 93 (89.4%)             | 51 (98.1%)            | 42 (80.8%)          | .004    |
| Reticular pattern                       | 21 (20.2%)             | 18 (36.4%)            | 3 (5.8%)            | <.001   |
| Pleural effusion                        | 4 (3.8%)               | 4 (7.7%)              | 0 (0.0%)            | .126    |

Note: The results were described as median and interquartile ranges, mean and standard deviations or numbers and percentages, as appropriate. Abbreviation: COVID-19, novel coronavirus disease 2019.

The prediction probability of age and neutrophilic percentage for severe type obtained by logistic regression analysis. The predictive value of 'age and neutrophilic percentage' was calculated using the following formula

\[ y = \frac{1}{1 + \exp(-x_0)} \] where \[ x_0 = \frac{1}{1 + \exp(-0.092 \times \text{age} - 0.091 \times \text{neutrophilic percentage})} \]

As this combined method was complicated for clinical application and the regression coefficients of age and neutrophilic percentage were similar, we further combined these two indicators as 'age + neutrophilic percentage' (the sum of age and neutrophilic percentage) and explored the predictive value for severe type. Age was in years, and neutrophilic percentage was in % in the two combination methods.

'Age + neutrophilic percentage' (AUC 0.900, 95% CI 0.825-0.950, P < .001) and 'age and neutrophilic percentage' (AUC 0.899, 95% CI 0.824-0.949, P < .001) presented excellent performances in predicting severe type, and the AUCs were higher than age, neutrophilic percentage, fever, duration from symptom onset to confirmation, respiratory rate, and SpO₂ with significant differences (all P < .05). The optimal cut-off for 'age + neutrophilic percentage' was >119.1 (sensitivity, 86.5%; specificity, 84.6%; Youden index, 0.712) (Table 5 and Figure 2).

4 | DISCUSSION

COVID-19 has resulted in considerable morbidity and mortality worldwide since December 2019. Monitoring the severity of COVID-19 and early effective intervention are fundamental measures for reducing mortality.

In this study, we reported the clinical characteristics and risk factors associated with severe COVID-19 including older age, comorbidities, surgical history, symptoms from onset to hospital admission.
(fever and expectoration), duration from symptom onset to confirmation, vital signs on hospital admission (respiratory rate, SpO₂ and the use of mechanical ventilation), chest CT findings on admission (bilateral infiltrates, ground-glass opacity and reticular pattern), and laboratory findings on admission (neutrophil percentage, neutrophil count, lymphocyte percentage, lymphocyte count, C-reactive protein, BUN and albumin). Older age, fever, duration from symptom onset to confirmation, respiratory rate, SpO₂ and neutrophilic percentage were independent predictors of severe COVID-19. Respiratory rate and SpO₂ are early and readily available indicators.
of lung injury. The delay in confirmation hinders early treatment of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may lead to deterioration of the condition. Consistent with the results of other studies, fever was associated with the development of severe type.7,8 However, the difference in patient temperature on hospital admission between the groups was small, which may be related to the use of antipyretic drugs before admission. Moreover, the performance of fever, duration from symptom onset to confirmation, and respiratory rate in predicting severe COVID-19 was poor and that of SpO₂ was good.

Older age and neutrophilic percentage performed best in predicting severe COVID-19. SARS-CoV-2 binds to the ACE2 receptor...
and enters the alveolar epithelial cells, leading to the release of the inducing factors and chemokines and activation of the abundant immune cells, leading to inflammation and tissue damage. Cytokine storm and viral evasion of cellular immune responses are thought to play important roles in disease severity. SARS-CoV-2 might mainly act on lymphocytes, especially T lymphocytes, resulting in a significant decrease in the number of T cells, which is further hampered in severe cases. The significant decrease in the number and percentage of peripheral lymphocytes in patients with COVID-19 may be related to the redistribution and increased consumption of lymphocytes and defective haemopoiesis. Neutrophils are the main source of chemokines and cytokines. In addition, reduced lymphocyte levels and impaired immune cell function in patients with severe COVID-19 may make them more sensitive to bacterial infection, which leads to a significant increase in neutrophil count. The neutrophil percentage had the best predictive performance for severe COVID-19, possibly because it reflects both lymphocytic decline and neutrophil elevation. Older age was associated with both severity and death. Besides older age is associated with reduced immune competence, elderly patients often have coexisting medical conditions, which were associated with severe COVID-19.

The combined parameters of age and neutrophil percentage performed better in predicting severe COVID-19 than these parameters alone and significantly better than single indicators, possibly because age and neutrophil percentage reflect the severity of inflammation and susceptibility of the population, respectively. In this study, we explored two ways in which age and neutrophilic percentage can be combined. ‘Age and neutrophilic percentage’ were derived from logistic regression analysis, which may be the best method of combination but was complex and clinically impractical. ‘Age + neutrophilic percentage’, which was the sum of age and neutrophil percentage, was recommended for clinical application because of its excellent predictive value for severe COVID-19 and practicability.

In addition, there were fewer cases of exposure to confirmed patients, and cases with exposure to confirmed patients had shorter duration from symptom onset to confirmation in the severe type, which may be related to the timely follow-up of close contacts of confirmed patients so that their contacts can receive timely diagnosis and treatment. In terms of treatment, antibiotic therapy, glucocorticoid treatment and vasoactive drug administration were more common in the severe type, which is associated with a more intense inflammatory response, more severe haemodynamic disorders and more severe immune impairment in severe-type patients than in mild type. Thus, the clinical outcome was worse in the severe type with more extrapulmonary comorbidities and longer length of hospital stay than in the mild type.

Our study has several potential weaknesses. First, it was a retrospective study, and the number of patients in this study was small. To reduce research bias, the cases in our study were from 13 hospitals in Hebei Province rather than a single centre, and the cases were matched according to the hospitals they were admitted to and their gender. Thus, to some extent, the results of this study may give clinicians a hint for early screening of patients with a tendency to progress to severe disease. Second, the main indicators analysed in this study were those on hospital admission; therefore, many parameters, such as arterial blood gas, erythrocyte sedimentation rate and procalcitonin, were not included in the analysis because of missing data. Nevertheless, our results provide a moderate and important insight on this topic.

5 | CONCLUSIONS

The combination of age and neutrophil percentage could effectively predict severe COVID-19. The sum of age and neutrophil percentage was recommended for clinical application because of its excellent predictive value for severe COVID-19 and practicability.

ACKNOWLEDGEMENTS

Authors wish to acknowledge all patients and their families involved in this study. We are grateful to the Expert Panel of the COVID-19 of Hebei Province and all health care workers around the world. We also thank Health Care Committee of Hebei Province for data support, and the Department of Science and Technology of Hebei Province for financial support.

DISCLOSURES

The authors declare that there are no conflicts of interests regarding the publication of this paper.

AUTHOR CONTRIBUTIONS

Yuhong Chen and Zhenjie Hu were involved in design. Kun Zhang, Yuhong Chen, Zhigang Cai and Lixia Liu collected the epidemiological and clinical data. Haijun Zhi, Kun Zhang, Yuhong Chen and Zhongheng Zhang summarised the data and performed analysis. Yuhong Chen drafted the manuscript. Xixin Yan, Guijun Zhu and Zhenjie Hu revised the final manuscript.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The Ethics Commission of the Fourth Clinical Medical College of Hebei Medical University approved this study(2020KS002).

DATA AVAILABILITY STATEMENT

After publication, we could share the data to other researchers, and a statement will be needed for evaluating the reasonability and validity. With agreement of the corresponding author and designated hospitals to treat patients with COVID-19, raw data will be provided.

ORCID

Zhenjie Hu https://orcid.org/0000-0003-1404-5691

REFERENCES

1. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epidemiological characteristics of novel coronavirus pneumonia COVID-19. Zhonghua liu xing bing xue za zhi. 2020;41:139-144.
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020;395:1054-1062.
5. Chinese Clinical Guidelines for COVID Pneumonia Diagnosis and Treatment (7th edition). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. Accessed March 3, 2020.
6. Zhang Z. Univariate description and bivariate statistical inference: the first step delving into data. Ann Transl Med. 2016;4:91.
7. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127-20.
8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395:497-506.
9. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768.
10. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
11. Yao XH, Li TY, He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua bing li xue za zhi. 2020;49(5):411-417.
12. Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta. 2020;507:174-180.
13. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395:507-513.
14. Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128-132.
15. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med. 2020;180:934.
16. Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol. 2015;194:4073-4080.

How to cite this article: Chen Y, Zhi H, Zhang K, et al. Combined predictive performance of age and neutrophilic percentage on admission for severe novel coronavirus disease 2019. Int J Clin Pract. 2021;75:e14257. https://doi.org/10.1111/ijcp.14257